Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma
- PMID: 17298420
- DOI: 10.1111/j.1398-9995.2006.01254.x
Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma
Abstract
Background: Characterization of uncontrolled asthma burden in a natural treatment setting can influence treatment recommendations and clinical practice. The objective was to characterize and compare the economic burden of severe or difficult-to-treat asthma in uncontrolled and controlled patients.
Methods: Baseline patient data (age > or = 13 years; n = 3916) were obtained from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens study. Disease control was assessed using two approaches: (i) applying criteria for control based on the Gaining Optimal Asthma Control study, and (ii) using the Asthma Therapy Assessment Questionnaire (ATAQ) to identify the number of asthma control problems. Assessments were performed at baseline, and at months 12 and 24. Monetary values were assigned to productivity loss and medical resource use. Direct and indirect costs were aggregated over 24 months and compared using Student's t-test for continuous measures and chi-squared for categorical variables.
Results: Throughout the study, most patients had uncontrolled asthma (83% uncontrolled; 16% inconsistent control; 1.3% controlled). Controlled patients experienced fewer work or school absences and less healthcare resource use than uncontrolled patients at all study time points. Using the multilevel ATAQ control score, asthma costs increased directly with the number of asthma control problems. Costs for uncontrolled patients were more than double those of controlled patients throughout the study (14,212 vs 6,452 US Dollars; adjusted to 2002 Dollars; P < 0.0001).
Conclusions: This study demonstrated that few severe or difficult-to-treat asthma patients achieved control over a 2-year period and the economic consequence of uncontrolled disease is substantial.
Comment in
-
Control and severity: complementary approaches to asthma management.Allergy. 2007 Feb;62(2):116-9. doi: 10.1111/j.1398-9995.2006.01223.x. Allergy. 2007. PMID: 17298418 No abstract available.
Similar articles
-
The impact of uncontrolled asthma on absenteeism and health-related quality of life.J Asthma. 2009 Nov;46(9):861-6. doi: 10.3109/02770900903184237. J Asthma. 2009. PMID: 19905909
-
Assessing productivity loss and activity impairment in severe or difficult-to-treat asthma.Value Health. 2008 Mar-Apr;11(2):231-9. doi: 10.1111/j.1524-4733.2007.00229.x. Value Health. 2008. PMID: 18380635
-
Economic burden of impairment in children with severe or difficult-to-treat asthma.Ann Allergy Asthma Immunol. 2011 Aug;107(2):110-119.e1. doi: 10.1016/j.anai.2011.04.008. Epub 2011 Jun 2. Ann Allergy Asthma Immunol. 2011. PMID: 21802018 Clinical Trial.
-
Prevention of allergic disease in childhood: clinical and epidemiological aspects of primary and secondary allergy prevention.Pediatr Allergy Immunol. 2004 Jun;15 Suppl 16:4-5, 9-32. doi: 10.1111/j.1399-3038.2004.0148b.x. Pediatr Allergy Immunol. 2004. PMID: 15125698 Review.
-
Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment.Curr Med Res Opin. 2018 Dec;34(12):2075-2088. doi: 10.1080/03007995.2018.1505352. Epub 2018 Aug 16. Curr Med Res Opin. 2018. PMID: 30047292
Cited by
-
IFN-γ-induced JAK/STAT, but not NF-κB, signaling pathway is insensitive to glucocorticoid in airway epithelial cells.Am J Physiol Lung Cell Mol Physiol. 2015 Aug 15;309(4):L348-59. doi: 10.1152/ajplung.00099.2015. Epub 2015 Jun 19. Am J Physiol Lung Cell Mol Physiol. 2015. PMID: 26092996 Free PMC article.
-
The Saudi Initiative for Asthma - 2019 Update: Guidelines for the diagnosis and management of asthma in adults and children.Ann Thorac Med. 2019 Jan-Mar;14(1):3-48. doi: 10.4103/atm.ATM_327_18. Ann Thorac Med. 2019. PMID: 30745934 Free PMC article.
-
Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.J Allergy Clin Immunol. 2023 Mar;151(3):747-755. doi: 10.1016/j.jaci.2022.11.021. Epub 2022 Dec 17. J Allergy Clin Immunol. 2023. PMID: 36538979 Free PMC article.
-
Value of inhaled corticosteroid therapy in long-term asthma management.P T. 2010 Jul;35(7):377-416. P T. 2010. PMID: 20689625 Free PMC article.
-
Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations.Pharmacoeconomics. 2018 Aug;36(8):957-971. doi: 10.1007/s40273-018-0658-x. Pharmacoeconomics. 2018. PMID: 29736895
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical